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LETTER TO THE EDITORS
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm
Teresa Pinto-Almeida, M.D., Iolanda Fernandes, M.D., Madalena Sanches, M.D., 
Catarina Lau, M.D.
1, Margarida Lima, Ph.D.
1, Rosário Alves, M.D., Manuela Selores, M.D.
Departments of Dermatology, 
1Hematology, Centro Hospitalar do Porto-Hospital de Santo António, Porto, Portugal
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a 
rare, highly aggressive hematopoietic malignancy that is 
characterized by cutaneous and bone marrow involve-
ment and leukemic spread, representing 0.7% of primary 
cutaneous lymphomas
1. Formerly known as CD4＋/CD56＋ 
hematodermic neoplasm or blastic NK-cell lymphoma
2, 
BPDCN is derived from precursors of plasmacytoid 
dendritic cells and was only recently established as a 
distinct entity
3. 
A 74-year-old man presented with a 4-month history of 
asymptomatic cutaneous lesions that initially appeared on 
his face but progressively spread to his thorax and arms. 
He had no systemic symptoms. His medical history included 
peripheral arterial disease and dyslipidemia, for which he 
was on acenocumarol and rosuvastatin. Physical exami-
nation revealed infiltrated violaceous plaques and nodules 
on his face and thorax and firm subcutaneous nodules on 
his arms along with reticulated purpuric macules (Fig. 1). 
Axillary and submandibular lymph nodes were bilaterally 
palpable. Laboratory data disclosed severe normochromic 
normocytic anemia (hemoglobin, 4.4 g/dl), thrombo-
cytopenia (53×10
9/L), leukocytosis (16.48×10
9/L) with 
44% of morphologically immature atypical cells and 
elevated  β2-microglobulin (3.8 mg/L). Flow cytometry 
(FCM) of the skin cells and the peripheral blood showed 
35% and 37%, respectively, of cells with the following 
immunophenotype (Fig. 2A, B): positive CD45 (dim), 
CD4, CD56, CD123, CD7 (dim), HLA-DR, and CD38. 
Other T/NK (CD1a, CD2, CD3, TCR, CD5, CD8, CD16, 
CD94, CD161), B (CD19, CD20, CD79a), myeloid (CD11b, 
CD13, CD14, CD15, CD33, CD64, myeloperoxidase) and 
immature cell (CD34) markers tested negative. Histo-
pathology of a skin lesion showed a monomorphous 
diffuse infiltrate of large blastic cells with irregular nuclei 
occupying the entire dermis and infiltrating the subcu-
taneous tissue (Fig. 2C, D). Immunohistochemical analysis 
confirmed the presence of cells with the aforementioned 
immunophenotypic features. No chromosomal alterations 
were detected by cytogenetic analysis of peripheral blood 
cells. Computed tomography scans disclosed basal lung 
consolidation suggestive of malignant infiltration, medi-
astinal, hilar, axillary and retroperitoneal lymphadeno-
pathy, hepatomegaly, and splenomegaly, findings that were 
compatible with widespread disease. Bone marrow analysis 
was not performed once its involvement was confirmed 
by the altered peripheral blood profile. Together these 
findings fulfilled the requirements for the diagnosis of 
BPDCN. The patient started palliative chemotherapy with 
cytarabine and mitoxantrone but died 3 weeks later of 
multi-organ failure. 
BPDCN is a rapidly evolving disease that primarily affects 
the elderly. The clinical presentation is quite constant, 
with 90% of patients presenting with asymptomatic solitary/ 
multifocal cutaneous reddish-brown nodules or bruise-like 
lesions
4,5. Bone marrow is involved in most cases, and 
practically any organ can be affected. The disease follows 
a short course and fulminant leukemia is the common 
terminal stage
4-6. The diagnosis relies on the immuno-
phenotypic features of the malignant cells. FCM is pre-
ferred over immunohistochemical analysis since it allows 
for the examination of more markers and their intensity 
determination
7,8. The expression of CD4, CD56, and CD123 
in the absence of T-cell, B-cell, or myeloid markers defines 
BPDCN
4-8. The correct diagnosis implies an appropriate 
panel of antibodies; in contrast, insufficient knowledge on T Pinto-Almeida, et al
236 Ann Dermatol
Fig. 1. (A, B) Features of the 
cutaneous lesions on the face and 
thorax. (C) Highlight of one firm 
subcutaneous nodule on the right 
arm. 
this entity and inadequate immunophenotypic investiga-
tion can lead to the misdiagnosis of a different leukemia
8. 
Cytogenetic analysis is not helpful since no recurrent 
specific chromosomal aberrations were recognized
7,8. The 
prognosis of patients with BPDCN is poor, with a median 
survival of 12∼14 months regardless of treatment type
9. 
Acute lymphoblastic leukemia-type treatment regimens 
are advised and a promising initial response may occur, 
but is followed by quick relapse
6,9,10. Long-term remis-
sions have been rarely reported in younger patients who 
received acute leukemia-type induction therapy and allo-
geneic stem cell transplantation
9-11.
Although clarification of the immunophenotypic features 
of BPDCN has improved its recognition, this entity 
remains a diagnostic challenge. Cutaneous lesions are 
usually the only sign of the disease, so dermatologists 
should be knowledgeable about it and play a crucial role 
in uncovering this malignancy and avoiding diagnostic 
delays.
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Fig. 2. (A, B) Flow cytometry dot plots of peripheral blood (A) and skin (B) cells showing blastic plasmacytoid dendritic cells (blastic
plasmacytoid dendritic cell neoplasm, red dots), respectively, expressing CD45 (dim), CD4 (dim), CD56, CD123, and HLA-DR. (C, 
D) Histopathological examination of a cutaneous lesion. (C) Diffuse infiltrate occupying the entire dermis and infiltrating the 
subcutaneous tissue (hematoxylin and eosin stain [H&E]; original magnification, ×4). (D) Higher amplification of the large blastic 
cells with large irregular nuclei (H&E; original magnification, ×40). SSC: side scatter; FSC: forward scatter.